NEWRON PHARMACEUT. EO-20 (NP5) - Total Liabilities
Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) has total liabilities worth €51.19 Million EUR (≈ $59.85 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore NEWRON PHARMACEUT. EO-20 equity growth rate to track the company's year-over-year net asset growth rate.
NEWRON PHARMACEUT. EO-20 - Total Liabilities Trend (2021–2025)
This chart illustrates how NEWRON PHARMACEUT. EO-20's total liabilities have evolved over time, based on quarterly financial data. See NEWRON PHARMACEUT. EO-20 (NP5) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
NEWRON PHARMACEUT. EO-20 Competitors by Total Liabilities
The table below lists competitors of NEWRON PHARMACEUT. EO-20 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cion Investment Corp
NYSE:CION
|
USA | $1.18 Billion |
|
Tehmag Foods
TWO:1264
|
Taiwan | NT$1.43 Billion |
|
Jiang Su New Technology Co. Ltd.
SHE:301229
|
China | CN¥563.13 Million |
|
Tang Eng Iron Works Co Ltd
TWO:2035
|
Taiwan | NT$15.18 Billion |
|
Microvast Holdings Inc
NASDAQ:MVST
|
USA | $521.39 Million |
|
China Shengmu Organic Milk Limited
F:7OM
|
Germany | €4.17 Billion |
|
INTEKPLUS Co. Ltd
KQ:064290
|
Korea | ₩68.14 Billion |
|
Yaxing Chem
SHG:600319
|
China | CN¥2.57 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down NEWRON PHARMACEUT. EO-20's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NEWRON PHARMACEUT. EO-20 market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NEWRON PHARMACEUT. EO-20's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NEWRON PHARMACEUT. EO-20 (2021–2025)
The table below shows the annual total liabilities of NEWRON PHARMACEUT. EO-20 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €51.19 Million ≈ $59.85 Million |
-18.03% |
| 2024-12-31 | €62.45 Million ≈ $73.01 Million |
+11.97% |
| 2023-12-31 | €55.77 Million ≈ $65.21 Million |
+8.88% |
| 2022-12-31 | €51.23 Million ≈ $59.89 Million |
+8.12% |
| 2021-12-31 | €47.38 Million ≈ $55.39 Million |
-- |
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more